United Statesstate reportKS

Psychedelic research and access in

Kansas

Kansas remains a controlled-access state. Kansas law continues to list Schedule I substances under the state Uniform Controlled Substances Act, while ketamine remains in Schedule III.

Key Insights

  • 1

    Kansas has not enacted a psychedelic services or decriminalisation pathway; classical psychedelics remain generally controlled.

  • 2

    HB 2218 is a narrow, FDA-contingent pharmaceutical psilocybin bill, not a broader reform bill; it was still on General Orders in the House as of 18 May 2026.

  • 3

    KanCare has a defined SPRAVATO access pathway through pharmacy benefit and prior authorisation.

  • 4

    KU Health provides ordinary IV ketamine and esketamine care for treatment-resistant depression.

  • 5

    KU-linked faculty activity suggests research interest in psychedelic-adjacent therapeutics, but Kansas is not yet a verified policy-led access state.

Research Snapshot

Deep report

Blossom currently tracks 7 psychedelic clinical trials with verified sites in Kansas, including 1 active study.

Active trials
1

Verified state-linked study sites

Total trials
7

Linked trial records

Stakeholders
9

9 physical, 1 jurisdiction-linked

Events
0

Linked state-level events

Top Compounds

  • Esketamine(4)
  • 5-MeO-DMT(1)
  • Ketamine(1)
  • Psilocybin(1)

Top Study Topics

  • Treatment-Resistant Depression (TRD)(4)
  • Healthy Volunteers(1)
  • Safety & Risk Management(1)
  • Suicidality(1)

Active Trial Preview

View linked trials →

Access and Payment

Ketamine/esketamine access; no state-regulated classical psychedelic pathway

For patients, Kansas presently offers ordinary ketamine/esketamine care rather than classical psychedelic services. KanCare/Kansas Medicaid has a pharmacy benefit for SPRAVATO and maintains prior-authorisation criteria for treatment-resistant depression or major depressive disorder with acute suicidal ideation or behaviour. The University of Kansas Health System states that it offers both ketamine intravenous therapy and esketamine spray for depression that has not responded to other treatment, and it describes monitored administration lasting up to two hours for ketamine nasal spray.

Research signal

Available

Kansas’ verified research signal is strongest around ketamine/esketamine and adjacent psychiatry rather than live state-authorised classical psychedelic access. The University of Kansas Medical Center highlights both historical participation in pivotal esketamine work through the Wichita campus and current departmental interest in psychedelic therapeutics.

Ketamine / esketamine

Available

For patients, Kansas presently offers ordinary ketamine/esketamine care rather than classical psychedelic services. KanCare/Kansas Medicaid has a pharmacy benefit for SPRAVATO and maintains prior-authorisation criteria for treatment-resistant depression or major depressive disorder with acute suicidal ideation or behaviour.

No state service model

Not Available

No state-regulated psilocybin, MDMA or natural-medicine service model is verified for Kansas.

Classical psychedelics

Not Available

HB 2218 is the state’s most decision-relevant policy signal. The bill would exclude an FDA-approved crystalline polymorph psilocybin product from the ordinary definition of psilocybin and place it in Schedule IV under Kansas law.

Reimbursement / payment

Limited

Kansas has state-specific Medicaid or payer material relevant to esketamine, but current plan criteria should be rechecked before publication.

Policy and Access Timeline

State-level bills, laws, pilots, agency actions, and reimbursement details that shape real-world access.

  1. 1 Jan 2026

    ActiveTask Force

    House committee report issued on HB 2218

    House committee report issued on HB 2218.

    Kansas
    HB 2218 bill page→

Advocacy and Nonprofit Coverage

These organizations have jurisdiction-level policy, advisory, or nonprofit relevance in Kansas. They are separate from physical office locations.

International Alliance of MDMA Practitioners (MDMA Alliance)
Industry Association / Lobby GroupGlobalExplicit Psychedelic FocusOther

The MDMA Alliance is a practitioner-facing association centered on MDMA-assisted therapy, with a global membership model and a stated focus on legal, ethical, and clinical standards. It appears to function more as a field infrastructure and professional coordination body than a direct legislative campaign group, but it does publicly frame advocacy as part of its mission. Likely collaboration points include clinician education, implementation guidance, standards development, research translation, and practitioner networking for researchers, funders, policy groups, and patient communities interested in safe and equitable regulated access.

Medical Access Pathways / Health System Implementation Policy / Research and Evidence Policy Briefing / Public Education and Awareness

International Alliance of MDMA Practitioners (MDMA Alliance) - Official Website

Regulatory Status

Kansas remains a controlled-access state. Kansas law continues to list Schedule I substances under the state Uniform Controlled Substances Act, while ketamine remains in Schedule III. No broad decriminalisation or regulated psilocybin services framework was verified. The main verified policy movement is House Bill 2218, a narrow, trigger-style bill dealing with FDA-approved crystalline polymorph psilocybin. As of 18 May 2026, the official Kansas bill page showed HB 2218 “On General Orders in House”, not enacted. Committee materials make clear that the bill was designed to create a state rescheduling route for a specific future FDA-approved pharmaceutical product, not to legalise or decriminalise psilocybin generally.

Medical Access Summary

For patients, Kansas presently offers ordinary ketamine/esketamine care rather than classical psychedelic services. KanCare/Kansas Medicaid has a pharmacy benefit for SPRAVATO and maintains prior-authorisation criteria for treatment-resistant depression or major depressive disorder with acute suicidal ideation or behaviour.[1][2][3]

The University of Kansas Health System states that it offers both ketamine intravenous therapy and esketamine spray for depression that has not responded to other treatment, and it describes monitored administration lasting up to two hours for ketamine nasal spray. That is standard medical access under existing federal and state rules, not a state psychedelic programme. No lawful non-research route was verified for psilocybin, MDMA or related substances.[2][4][5]

Local Research Map

Mapped trial sites, physical stakeholders, and events linked to Kansas.

Policy and Access Context

HB 2218 is the state’s most decision-relevant policy signal. The bill would exclude an FDA-approved crystalline polymorph psilocybin product from the ordinary definition of psilocybin and place it in Schedule IV under Kansas law. The bill’s supporters explicitly argued that Kansas does not automatically follow future DEA rescheduling; the bill therefore functions as a precautionary state-law bridge for a hypothetical future approved product.[1][2][3]

That matters for professional readers because it shows Kansas policymakers are willing to contemplate pharmaceutical psilocybin before they are willing to contemplate broader reform. In practice, Kansas is still a no-service, no-decriminalisation state for classical psychedelics, with policy activity limited to medicalised, federal-approval-contingent legislation.[1][2][1]

Research Focus

Kansas’ verified research signal is strongest around ketamine/esketamine and adjacent psychiatry rather than live state-authorised classical psychedelic access. The University of Kansas Medical Center highlights both historical participation in pivotal esketamine work through the Wichita campus and current departmental interest in psychedelic therapeutics. A KU faculty profile states that Tyler Kjorvestad serves as Director of Clinical Trials and is principal investigator on a Reunion Neuroscience trial of RE104, a synthetic psilocybin analogue, in adjustment disorder in terminal illness.[1][2][3]

At care-delivery level, KU Health’s psychiatry service openly lists IV ketamine and esketamine among treatment-resistant depression options. That makes Kansas an interventional-psychiatry state with credible academic infrastructure, but not yet a verified classical-psychedelic trial hub on the scale of Maryland or Massachusetts-linked institutions.[2][4][3]

Implementation Context

Kansas has no state implementation apparatus for psilocybin services because HB 2218 has not been enacted and no broader psychedelic programme was verified. There are therefore no service-centre licences, facilitator rules or natural-medicine regulators to track.[1][2][3]

Implementation questions instead sit inside payer policy and provider capability. KanCare criteria, prior authorisation and billing rules shape actual access to SPRAVATO; KU Health’s existing ketamine/esketamine services show that provider-side infrastructure exists for interventional psychiatry. If Kansas ever advances a pharmaceutical-psilocybin trigger law, pharmacy, scheduling and prescriber implementation would be the first issues to watch.[4][5][1]

Ecosystem Context

The most important verified ecosystem actors are KU Health and KU Medical Center/Wichita. KU Health offers clinical ketamine and esketamine; KU Wichita has a documented role in esketamine development and houses leadership with explicit psychedelic-research interests.[1][2][3]

This research set did not verify a deeper Kansas-specific advocacy or service ecosystem comparable to states with municipal decriminalisation or regulated access debates. For conference, investment and media readers, Kansas currently looks like a conservative market with some academic and clinical sophistication, but limited policy breadth.[4][2][3]

Key Milestones

Jan 2022
KanCare adds a pharmacy benefit for SPRAVATO.
Feb 2025
Kansas House Health and Human Services hears HB 2218.
Jan 2026
House committee report issued on HB 2218.
May 2026
HB 2218 remains on General Orders in the House.

Future Outlook

Kansas is likely to remain a cautious, product-specific state over the next 12 to 24 months. The main live policy variable is whether HB 2218 or a similar bill survives; if not, Kansas will stay reliant on federal approval plus later state-law action.[1][2][3]

Access growth is more likely to come from ordinary interventional psychiatry than from psychedelic law reform. That means any near-term expansion would probably be more SPRAVATO capacity, more ketamine clinics, and perhaps more academic trial participation rather than any natural-medicine framework.[4][1][3]

Sources and Review

Last updated 18 May 2026. Source links come from the subnational report.

  1. 1HB 2218 bill page
  2. 2HB 2218 committee minutes
  3. 3K.S.A. 65-4109
  4. 4KMAP Spravato Coverage Update / KDHE PA criteria
  5. 5KU Health Psychiatry / Ketamine nasal spray pages
  6. 6Tyler Kjorvestad faculty profile